PortalPublikationenSize of lymph-node metastases in prostate cancer patients un...

Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: implication for imaging and oncologic follow-up of 2705 lymph-node positive patients

Standard

Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: implication for imaging and oncologic follow-up of 2705 lymph-node positive patients. / Falkenbach, Fabian; Kachanov, Mykyta; Leyh-Bannurah, Sami-Ramzi; Maurer, Tobias; Knipper, Sophie; Köhler, Daniel; Graefen, Markus; Sauter, Guido; Budäus, Lars.

in: WORLD J UROL, Jahrgang 42, Nr. 1, 38, 20.01.2024.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Falkenbach, F, Kachanov, M, Leyh-Bannurah, S-R, Maurer, T, Knipper, S, Köhler, D, Graefen, M, Sauter, G & Budäus, L 2024, 'Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: implication for imaging and oncologic follow-up of 2705 lymph-node positive patients', WORLD J UROL, Jg. 42, Nr. 1, 38. https://doi.org/10.1007/s00345-023-04724-1

APA

Falkenbach, F., Kachanov, M., Leyh-Bannurah, S-R., Maurer, T., Knipper, S., Köhler, D., Graefen, M., Sauter, G., & Budäus, L. (2024). Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: implication for imaging and oncologic follow-up of 2705 lymph-node positive patients. WORLD J UROL, 42(1), [38]. https://doi.org/10.1007/s00345-023-04724-1

Vancouver

Falkenbach F, Kachanov M, Leyh-Bannurah S-R, Maurer T, Knipper S, Köhler D et al. Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: implication for imaging and oncologic follow-up of 2705 lymph-node positive patients. WORLD J UROL. 2024 Jan 20;42(1). 38. https://doi.org/10.1007/s00345-023-04724-1

Bibtex

@article{f7c91c4ab1784b138550e3b856287220,
title = "Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: implication for imaging and oncologic follow-up of 2705 lymph-node positive patients",
abstract = "BACKGROUND: Despite modern imaging modalities, lymph-node staging before radical prostatectomy (RP) remains challenging in patients with prostate cancer (PCa). The visibility of lymph-node metastases (LNMs) is critically influenced by their size.OBJECTIVE: This study aims to describe the distribution of maximal tumor diameters (i.e., size) in LNMs of pN1-PCa at RP and its consequences on visibility in preoperative imaging and oncological outcomes.DESIGN, SETTING, AND PARTICIPANTS: A total of 2705 consecutive patients with pN1-PCa at RP, harboring a cumulative 7510 LNMs, were analyzed. Descriptive and multivariable analyses addressed the risk of micrometastases (MM)-only disease and the visibility of LNMs. Kaplan-Meier curves and Cox analyses were used for biochemical recurrence-free survival (BCRFS) stratified for MM-only disease.RESULTS: The median LNM size was 4.5mm (interquartile range (IQR): 2.0-9.0 mm). Of 7510 LNMs, 1966 (26%) were MM (≤ 2mm). On preoperative imaging, 526 patients (19%) showed suspicious findings (PSMA-PET/CT: 169/344, 49%). In multivariable analysis, prostate-specific antigen (PSA) (OR 0.98), age (OR 1.01), a Gleason score greater than 7 at biopsy (OR 0.73), percentage of positive cores at biopsy (OR 0.36), and neoadjuvant treatment (OR 0.51) emerged as independent predictors for less MM-only disease (p < 0.05). Patients with MM-only disease compared to those harboring larger LNMs had a longer BCRFS (median 60 versus 29 months, p < 0.0001).CONCLUSION: Overall, 26% of LNMs were MM (≤ 2mm). Adverse clinical parameters were inversely associated with MM at RP. Consequently, PSMA-PET/CT did not detect a substantial proportion of LNMs. LNM size and count are relevant for prognosis.",
keywords = "Male, Humans, Positron Emission Tomography Computed Tomography/methods, Follow-Up Studies, Lymphatic Metastasis/pathology, Prostatic Neoplasms/diagnostic imaging, Lymph Nodes/pathology, Prostatectomy, Lymph Node Excision/methods, Retrospective Studies",
author = "Fabian Falkenbach and Mykyta Kachanov and Sami-Ramzi Leyh-Bannurah and Tobias Maurer and Sophie Knipper and Daniel K{\"o}hler and Markus Graefen and Guido Sauter and Lars Bud{\"a}us",
note = "{\textcopyright} 2024. The Author(s).",
year = "2024",
month = jan,
day = "20",
doi = "10.1007/s00345-023-04724-1",
language = "English",
volume = "42",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: implication for imaging and oncologic follow-up of 2705 lymph-node positive patients

AU - Falkenbach, Fabian

AU - Kachanov, Mykyta

AU - Leyh-Bannurah, Sami-Ramzi

AU - Maurer, Tobias

AU - Knipper, Sophie

AU - Köhler, Daniel

AU - Graefen, Markus

AU - Sauter, Guido

AU - Budäus, Lars

N1 - © 2024. The Author(s).

PY - 2024/1/20

Y1 - 2024/1/20

N2 - BACKGROUND: Despite modern imaging modalities, lymph-node staging before radical prostatectomy (RP) remains challenging in patients with prostate cancer (PCa). The visibility of lymph-node metastases (LNMs) is critically influenced by their size.OBJECTIVE: This study aims to describe the distribution of maximal tumor diameters (i.e., size) in LNMs of pN1-PCa at RP and its consequences on visibility in preoperative imaging and oncological outcomes.DESIGN, SETTING, AND PARTICIPANTS: A total of 2705 consecutive patients with pN1-PCa at RP, harboring a cumulative 7510 LNMs, were analyzed. Descriptive and multivariable analyses addressed the risk of micrometastases (MM)-only disease and the visibility of LNMs. Kaplan-Meier curves and Cox analyses were used for biochemical recurrence-free survival (BCRFS) stratified for MM-only disease.RESULTS: The median LNM size was 4.5mm (interquartile range (IQR): 2.0-9.0 mm). Of 7510 LNMs, 1966 (26%) were MM (≤ 2mm). On preoperative imaging, 526 patients (19%) showed suspicious findings (PSMA-PET/CT: 169/344, 49%). In multivariable analysis, prostate-specific antigen (PSA) (OR 0.98), age (OR 1.01), a Gleason score greater than 7 at biopsy (OR 0.73), percentage of positive cores at biopsy (OR 0.36), and neoadjuvant treatment (OR 0.51) emerged as independent predictors for less MM-only disease (p < 0.05). Patients with MM-only disease compared to those harboring larger LNMs had a longer BCRFS (median 60 versus 29 months, p < 0.0001).CONCLUSION: Overall, 26% of LNMs were MM (≤ 2mm). Adverse clinical parameters were inversely associated with MM at RP. Consequently, PSMA-PET/CT did not detect a substantial proportion of LNMs. LNM size and count are relevant for prognosis.

AB - BACKGROUND: Despite modern imaging modalities, lymph-node staging before radical prostatectomy (RP) remains challenging in patients with prostate cancer (PCa). The visibility of lymph-node metastases (LNMs) is critically influenced by their size.OBJECTIVE: This study aims to describe the distribution of maximal tumor diameters (i.e., size) in LNMs of pN1-PCa at RP and its consequences on visibility in preoperative imaging and oncological outcomes.DESIGN, SETTING, AND PARTICIPANTS: A total of 2705 consecutive patients with pN1-PCa at RP, harboring a cumulative 7510 LNMs, were analyzed. Descriptive and multivariable analyses addressed the risk of micrometastases (MM)-only disease and the visibility of LNMs. Kaplan-Meier curves and Cox analyses were used for biochemical recurrence-free survival (BCRFS) stratified for MM-only disease.RESULTS: The median LNM size was 4.5mm (interquartile range (IQR): 2.0-9.0 mm). Of 7510 LNMs, 1966 (26%) were MM (≤ 2mm). On preoperative imaging, 526 patients (19%) showed suspicious findings (PSMA-PET/CT: 169/344, 49%). In multivariable analysis, prostate-specific antigen (PSA) (OR 0.98), age (OR 1.01), a Gleason score greater than 7 at biopsy (OR 0.73), percentage of positive cores at biopsy (OR 0.36), and neoadjuvant treatment (OR 0.51) emerged as independent predictors for less MM-only disease (p < 0.05). Patients with MM-only disease compared to those harboring larger LNMs had a longer BCRFS (median 60 versus 29 months, p < 0.0001).CONCLUSION: Overall, 26% of LNMs were MM (≤ 2mm). Adverse clinical parameters were inversely associated with MM at RP. Consequently, PSMA-PET/CT did not detect a substantial proportion of LNMs. LNM size and count are relevant for prognosis.

KW - Male

KW - Humans

KW - Positron Emission Tomography Computed Tomography/methods

KW - Follow-Up Studies

KW - Lymphatic Metastasis/pathology

KW - Prostatic Neoplasms/diagnostic imaging

KW - Lymph Nodes/pathology

KW - Prostatectomy

KW - Lymph Node Excision/methods

KW - Retrospective Studies

U2 - 10.1007/s00345-023-04724-1

DO - 10.1007/s00345-023-04724-1

M3 - SCORING: Journal article

C2 - 38244095

VL - 42

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 1

M1 - 38

ER -